The Global Gonorrhea Therapeutics Market Report is equipped with market data from 2014 to 2024. The report gives a market overview covering key drivers and risks factors. The report is bifurcated by top global manufactures mentioning sales, revenue and prices as applicable. It also evaluates the competitive scenario of the leading players. The report expands to cover regional market data along with type and application. The report forecasts sales and revenue from 2019 to 2024. The detailed sales channel is also covered in the study.
Gonorrhea is a sexually transmitted disease (STD) that affects both men and women. The infection affects the genitals, rectum, and the throat. The treatment landscape typically involves the use of antibiotics with dual therapy dominating the market compared with monotherapy. As the market has a deep penetration of generics, the growth rate is expected to be moderate during the forecast period. Additionally, the advent of new antibiotic-resistant strains will continue to hinder the growth prospects.
Scope of the Report:
The latest trend gaining momentum in the market is Advent of vaccine for prevention of gonorrhea. Gonorrhea is a major public health concern globally. It is considerably affecting the reproductive health of people and increasing the spread of human immunodeficiency virus (HIV). The currently available treatment regimen is unsuccessful in controlling the spread of Neisseria gonorrhoeae due to the rapid emergence of the antibiotic-resistant strains of this bacterium. Therefore, the prevention of the disease seems to be a more appropriate approach for controlling the spread of Neisseria gonorrhoeae.
One of the major drivers for this market is Rising prevalence of disease. The rising prevalence of gonorrhea is a major health concern globally. The disease follows chlamydial infection as the second most common STD in the US. The rising prevalence rate of gonorrhea is due to several factors such as growing awareness, increased healthcare access, availability of diagnostic tests, resistance patterns, reporting practices, and the financial constraints that limit the abilities of public healthcare officials to check the disease pattern precisely.
The global Gonorrhea Therapeutics market is valued at xx million USD in 2018 and is expected to reach xx million USD by the end of 2024, growing at a CAGR of xx% between 2019 and 2024.
The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.
North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Gonorrhea Therapeutics.
Europe also play important roles in global market, with market size of xx million USD in 2019 and will be xx million USD in 2024, with a CAGR of xx%.
This report studies the Gonorrhea Therapeutics market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Gonorrhea Therapeutics market by product type and applications/end industries.
Market Segment by Companies, this report covers
- Bharat Pharmaceuticals
- GlaxoSmithKline
- Merck
- Pfizer
- Alopexx Pharmaceuticals
- AstraZeneca
- Debiopharm Group
- Melinta Therapeutics
Market Segment by Regions, regional analysis covers
- North America (United States, Canada and Mexico)
- Europe (Germany, France, UK, Russia and Italy)
- Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
- South America (Brazil, Argentina, Colombia)
- Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Market Segment by Applications, can be divided into